Imaging markers for Alzheimer disease
暂无分享,去创建一个
Martina Bocchetta | Clifford R Jack | Frederik Barkhof | Karl Herholz | Nick C Fox | Eric M Reiman | Keith A. Johnson | Philip Scheltens | Christopher C Rowe | Sandra E Black | Gil D Rabinovici | William J Jagust | Michael W Weiner | Jeffrey Kaye | Lars-Olof Wahlund | Mony J de Leon | David J Brooks | Giovanni B Frisoni | Agneta Nordberg | Keith A Johnson | P. Pasqualetti | S. Black | C. Jack | M. Weiner | W. Jagust | M. Carrillo | C. Rowe | P. Scheltens | R. Sperling | F. Barkhof | J. Kaye | G. Frisoni | W. Thies | E. Reiman | K. Herholz | M. D. de Leon | L. Wahlund | D. Brooks | G. Chételat | M. Bocchetta | G. Rabinovici | A. Nordberg | C. DeCarli | Patrizio Pasqualetti | Reisa A Sperling | William Thies | Gael Chételat | Charles Decarli | Maria C Carrillo | S. Black
[1] Michael D. Devous,et al. Functional brain imaging in the dementias: role in early detection, differential diagnosis, and longitudinal studies , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[2] Juha Koikkalainen,et al. Combination of Biomarkers: PET [18F]Flutemetamol Imaging and Structural MRI in Dementia and Mild Cognitive Impairment , 2012, Neurodegenerative Diseases.
[3] Jean-Claude Baron,et al. Early diagnosis of alzheimer’s disease: contribution of structural neuroimaging , 2003, NeuroImage.
[4] Nick C Fox,et al. The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease , 2011 .
[5] Marie Chupin,et al. Automatic classi fi cation of patients with Alzheimer ' s disease from structural MRI : A comparison of ten methods using the ADNI database , 2010 .
[6] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[7] Lucie Yang,et al. Brain amyloid imaging--FDA approval of florbetapir F18 injection. , 2012, The New England journal of medicine.
[8] N. Bohnen,et al. Effectiveness and Safety of 18F-FDG PET in the Evaluation of Dementia: A Review of the Recent Literature , 2012, The Journal of Nuclear Medicine.
[9] Dominique Hasboun,et al. Anatomically constrained region deformation for the automated segmentation of the hippocampus and the amygdala: Method and validation on controls and patients with Alzheimer’s disease , 2007, NeuroImage.
[10] G. Guyatt,et al. Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. , 1994, JAMA.
[11] Z. Khachaturian. Revised criteria for diagnosis of Alzheimer’s disease: National Institute on Aging-Alzheimer's Association diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[12] C. Jack,et al. Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance , 2012, Neurobiology of Aging.
[13] Hans-Peter Meinzer,et al. Automated MR morphometry to predict Alzheimer’s disease in mild cognitive impairment , 2010, International Journal of Computer Assisted Radiology and Surgery.
[14] A. Convit,et al. Reduced hippocampal metabolism in MCI and AD , 2005, Neurology.
[15] Dong Han,et al. Diagnostic accuracy of 18F‐FDG and 11C‐PIB‐PET for prediction of short‐term conversion to Alzheimer’s disease in subjects with mild cognitive impairment , 2012, International journal of clinical practice.
[16] M. Yoshita,et al. A Comparison of the Diagnostic Sensitivity of MRI, CBF-SPECT, FDG-PET and Cerebrospinal Fluid Biomarkers for Detecting Alzheimer’s Disease in a Memory Clinic , 2010, Dementia and Geriatric Cognitive Disorders.
[17] W. Xu,et al. Association Study of Clusterin Polymorphism rs11136000 With Late Onset Alzheimer’s Disease in Chinese Han Population , 2011, American journal of Alzheimer's disease and other dementias.
[18] Nick C Fox,et al. Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.
[19] Keith A. Johnson,et al. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer’s disease , 2011, Alzheimer's & Dementia.
[20] Michael J Daniels,et al. A Bayesian Semiparametric Approach for Incorporating Longitudinal Information on Exposure History for Inference in Case–Control Studies , 2012, Biometrics.
[21] Denise C. Park,et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[22] et al.,et al. Discrimination between Alzheimer Dementia and Controls by Automated Analysis of Multicenter FDG PET , 2002, NeuroImage.
[23] Klaus P. Ebmeier,et al. Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia. , 2004, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[24] B. Winblad,et al. Revised criteria for Alzheimer's disease: what are the lessons for clinicians? , 2011, The Lancet Neurology.
[25] G. Rabinovici,et al. Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications , 2011, Alzheimer's Research & Therapy.
[26] G. Guyatt,et al. Users' Guides to the Medical Literature: III. How to Use an Article About a Diagnostic Test: B. What Are the Results and Will They Help Me In Caring for My Patients? , 1994 .
[27] David Manset,et al. Virtual imaging laboratories for marker discovery in neurodegenerative diseases , 2011, Nature Reviews Neurology.
[29] Jim Albert,et al. Bayesian Computation with R , 2008 .
[30] L. Mosconi,et al. Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[31] A M Dale,et al. Measuring the thickness of the human cerebral cortex from magnetic resonance images. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[32] Karl Herholz,et al. Clinical amyloid imaging in Alzheimer's disease , 2011, The Lancet Neurology.
[33] A. Korczyn. Commentary on “Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.” , 2011, Alzheimer's & Dementia.
[34] L. Mucke,et al. 100 Years and Counting: Prospects for Defeating Alzheimer's Disease , 2006, Science.
[35] R. Coleman,et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study , 2012, The Lancet Neurology.
[36] Clifford R. Jack,et al. Alliance for Aging Research AD Biomarkers Work Group: structural MRI , 2011, Neurobiology of Aging.
[37] Sean D Sullivan,et al. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.
[38] C. Patterson,et al. Commentary on “Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.” A Canadian perspective , 2011, Alzheimer's & Dementia.
[40] Y. Yuan,et al. Fluorodeoxyglucose–Positron-Emission Tomography, Single-Photon Emission Tomography, and Structural MR Imaging for Prediction of Rapid Conversion to Alzheimer Disease in Patients with Mild Cognitive Impairment: A Meta-Analysis , 2008, American Journal of Neuroradiology.
[41] Cees Jonker,et al. Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment , 1999, Journal of Neurology.
[42] Paul M. Thompson,et al. Characterizing Alzheimer's disease using a hypometabolic convergence index , 2011, NeuroImage.
[43] Michael Weiner,et al. and the Alzheimer’s Disease Neuroimaging Initiative* , 2007 .
[44] B. Winblad,et al. Revised NIA-AA criteria for the diagnosis of Alzheimer's disease: a step forward but not yet ready for widespread clinical use , 2011, International Psychogeriatrics.
[45] P. Scheltens,et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.
[46] J Schröder,et al. Age and diagnostic performance of Alzheimer disease CSF biomarkers , 2012, Neurology.
[47] G. Samsa,et al. Alzheimer disease: operating characteristics of PET--a meta-analysis. , 2004, Radiology.